Table 1.
Selected OGTT metabolic, demographic, and clinical variables by treatment group at baseline
| Glimepiride | Liraglutide | Sitagliptin | P (ANOVA or χ2)* | |
|---|---|---|---|---|
| Baseline (n) | 1,254 | 1,262 | 1,268 | |
| Age (years) | 57.1 ± 10.1 | 57.4 ± 9.9 | 57.2 ± 10.1 | 0.704 |
| Female sex | 476 (38.0) | 439 (34.8) | 470 (37.1) | 0.234 |
| Race | 0.395 | |||
| American Indian/Alaska Native | 30 (2.4) | 40 (3.2) | 34 (2.7) | |
| Asian/Hawaiian/Pacific Islander | 54 (4.3) | 55 (4.4) | 62 (4.9) | |
| Black or African American | 271 (21.6) | 251 (19.9) | 225 (17.7) | |
| Other/unknown | 91 (7.3) | 101 (8.0) | 93 (7.3) | |
| White | 808 (64.4) | 815 (64.6) | 854 (67.4) | |
| Hispanic ethnicity | 234 (18.9) | 234 (18.6) | 241 (19.2) | 0.945 |
| Diabetes duration (years) | 4.3 ± 2.8 | 4.2 ± 2.7 | 4.2 ± 2.7 | 0.422 |
| BMI (kg/m2) | 34.3 ± 6.9 | 34.3 ± 6.7 | 34.1 ± 6.8 | 0.694 |
| HbA1c, % (mmol/mol) | 7.5 ± 0.5 (58.2 ± 5.2) | 7.5 ± 0.5 (58.4 ± 5.3) | 7.5 ± 0.5 (58.4 ± 5.3) | 0.417 |
| Fasting glucose (mg/dL) | 151.2 ± 31.2 (n = 1,251) | 150.9 ± 30.6 (n = 1,253) | 151.1 ± 29.6 (n = 1,258) | 0.968 |
| Fasting CP (nmol/L) | 1.3 ± 0.6 (n = 1,250) | 1.3 ± 0.5 (n = 1,253) | 1.3 ± 0.6 (n = 1,257) | 0.708 |
| HOMA2-%S based on CP | 34.4 ± 15.9 (n = 1,250) | 34.8 ± 16.3 (n = 1,252) | 34.3 ± 15.5 (n = 1,257) | 0.714 |
| CPI (nmol/g) | 0.7 ± 0.5 (n = 1,149) | 0.8 ± 0.5 (n = 1,190) | 0.8 ± 0.5 (n = 1,194) | 0.525 |
| Total CP response (nmol/mg) | 1.1 ± 0.6 (n = 1,109) | 1.0 ± 0.6 (n = 1,162) | 1.1 ± 0.6 (n = 1,157) | 0.462 |
Data are means ± SD for continuous variables or n (%) for categorical variables unless otherwise indicated. For OGTT measures (fasting glucose, fasting CP, HOMA2-%S, CPI, total CP response), available n for each baseline measure is provided in parentheses.
*ANOVA global F test for differences in means (continuous variables) or χ2 test for differences in proportions (categorical variables) among the four treatment groups.